CN1171587C - 含有γ-氨基丁酸衍生物的固体组合物及其制备方法 - Google Patents

含有γ-氨基丁酸衍生物的固体组合物及其制备方法 Download PDF

Info

Publication number
CN1171587C
CN1171587C CNB998059781A CN99805978A CN1171587C CN 1171587 C CN1171587 C CN 1171587C CN B998059781 A CNB998059781 A CN B998059781A CN 99805978 A CN99805978 A CN 99805978A CN 1171587 C CN1171587 C CN 1171587C
Authority
CN
China
Prior art keywords
amino
wetting agent
acid derivative
butanoic acid
glycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998059781A
Other languages
English (en)
Chinese (zh)
Other versions
CN1300213A (zh
Inventor
���ɻ�
青松晃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1171587(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1300213A publication Critical patent/CN1300213A/zh
Application granted granted Critical
Publication of CN1171587C publication Critical patent/CN1171587C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Arrangement Of Transmissions (AREA)
  • Body Structure For Vehicles (AREA)
CNB998059781A 1998-05-15 1999-05-10 含有γ-氨基丁酸衍生物的固体组合物及其制备方法 Expired - Fee Related CN1171587C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP133122/1998 1998-05-15
JP13312298A JP3761324B2 (ja) 1998-05-15 1998-05-15 乗用田植機

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB200410077021XA Division CN100337687C (zh) 1998-05-15 1999-05-10 含有γ－氨基丁酸衍生物的固体组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN1300213A CN1300213A (zh) 2001-06-20
CN1171587C true CN1171587C (zh) 2004-10-20

Family

ID=15097314

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998059781A Expired - Fee Related CN1171587C (zh) 1998-05-15 1999-05-10 含有γ-氨基丁酸衍生物的固体组合物及其制备方法

Country Status (16)

Country Link
JP (1) JP3761324B2 (es)
CN (1) CN1171587C (es)
AT (1) ATE407668T1 (es)
CA (1) CA2325045C (es)
CY (1) CY1108488T1 (es)
DE (1) DE69939532D1 (es)
DK (1) DK1077691T3 (es)
EA (1) EA006553B1 (es)
EE (1) EE05530B1 (es)
EG (1) EG26287A (es)
ES (1) ES2312208T3 (es)
GE (1) GEP20032987B (es)
IL (2) IL139202A0 (es)
NZ (1) NZ507162A (es)
PT (1) PT1077691E (es)
UA (1) UA76398C2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4904636B2 (ja) * 2001-05-29 2012-03-28 井関農機株式会社 トラクタフレーム
JP5047022B2 (ja) * 2008-03-24 2012-10-10 ヤンマー株式会社 上下分割式のエンジン収納用パッケージの結合構造
WO2013008182A1 (en) * 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
SG11201407303SA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
EP2847169A4 (en) 2012-05-07 2015-09-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168010A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CN104352476A (zh) * 2014-10-21 2015-02-18 齐宏 一种加巴喷丁胶囊及其制备方法
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107428697A (zh) 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法

Also Published As

Publication number Publication date
PT1077691E (pt) 2008-11-04
JPH11318133A (ja) 1999-11-24
EE05530B1 (et) 2012-04-16
ES2312208T3 (es) 2009-02-16
ATE407668T1 (de) 2008-09-15
CA2325045C (en) 2005-05-03
NZ507162A (en) 2003-11-28
EE200000671A (et) 2002-04-15
EG26287A (en) 2013-06-12
UA76398C2 (en) 2006-08-15
IL139202A (en) 2014-12-31
DK1077691T3 (da) 2008-10-27
EA006553B1 (ru) 2006-02-24
GEP20032987B (en) 2003-06-25
JP3761324B2 (ja) 2006-03-29
CY1108488T1 (el) 2014-04-09
CA2325045A1 (en) 1999-11-25
IL139202A0 (en) 2001-11-25
CN1300213A (zh) 2001-06-20
EA200001154A1 (ru) 2001-06-25
DE69939532D1 (de) 2008-10-23

Similar Documents

Publication Publication Date Title
CN1171587C (zh) 含有γ-氨基丁酸衍生物的固体组合物及其制备方法
CN100337687C (zh) 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
CN1303991C (zh) γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
CN1182841C (zh) 新的药物制剂及其制备方法
CN1222290C (zh) 新组合物及其用途
CN1194687C (zh) 含有阿莫西林和克拉维酸盐的药物制剂
CN100335043C (zh) 片剂化多重单元泡腾剂剂型口服药物组合物及其生产方法
CN1020852C (zh) 用作口服的新的药用制剂
CN1126543C (zh) 用于口服给药n－哌啶子基－3－吡唑甲酰胺衍生物、其盐及其溶剂化物的药物组合物
CN1154490C (zh) 塞内昔布组合物
CN1068305C (zh) 制备其对映体纯度大于90％的s(－)2－(4－异丁基苯基)丙酸钠的方法
CN1160058C (zh) 附聚物
CN1023765C (zh) 持久释药的基质配方
CN101036633A (zh) 一种奥美拉唑肠溶微丸胶囊及其制备方法
CN1076124A (zh) 一种用于制备含有酸不稳定化合物的肠溶衣口服药的方法
CN1633282A (zh) 可分散在口中的泡腾片剂
CN1767819A (zh) 包含s1p受体激动剂和糖醇的固体药物组合物
CN1652752A (zh) 盐酸纳曲酮组合物
CN1929821A (zh) 包含匹莫苯的药物组合物
CN1518442A (zh) 含有环孢菌素的药物组合物
CN1852703A (zh) 含有双胍和噻唑烷二酮衍生物的新型药物配方
CN1679525A (zh) 复方对乙酰氨基酚口腔崩解片
CN1159004C (zh) 具有高含量n-乙酰半胱氨酸的可吞咽片剂
CN1585639A (zh) 抗疟疾制剂
CN1823805A (zh) 一种地红霉素肠溶微丸及制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1998.05.15 JP 133112/1998

False: 1998.05.15 JP 133122/1998

Number: 42

Page: 411

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1998.05.15 JP 133112/1998

False: 1998.05.15 JP 133122/1998

Number: 42

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: 1998.5.15 JAPAN 133122/1998 TO: 1998.5.15 JAPAN 133112/1998

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: 1998.5.15 JAPAN 133122/1998 TO: 1998.5.15 JAPAN 133112/1998

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041020

Termination date: 20180510

CF01 Termination of patent right due to non-payment of annual fee